Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as plannedMore than half of planned participants have completed dosing with no dose reductions, discontinuations, drug-related SAEs, loss of consciousness, or excessive sedation reportedTopline…